Corcept Therapeutics Inc. (CORT) announced on Monday successful results from its Phase 3 long-term extension study concerning relacorilant, a treatment for patients suffering from endogenous hypercortisolism, a condition triggered by an overproduction of the hormone cortisol.
The study revealed that patients undergoing treatment with relacorilant exhibited significant and lasting improvements in cardiometabolic health. The medication demonstrated good tolerability over a treatment period extending up to six years.
Additionally, participants showed enhanced blood pressure levels while consistently maintaining positive outcomes in other cardiometabolic indicators, including glycemic control and body weight management.
As of the latest trading session, Corcept's shares are valued at $54.95, reflecting a decrease of 0.81 percent on Nasdaq.
